Knight Therapeutics (GUD) Reaches New 12-Month Low at $7.35

Share on StockTwits

Shares of Knight Therapeutics Inc (TSE:GUD) reached a new 52-week low during mid-day trading on Friday . The stock traded as low as C$7.35 and last traded at C$7.40, with a volume of 145819 shares trading hands. The stock had previously closed at C$7.55.

Separately, Raymond James set a C$10.25 price target on shares of Knight Therapeutics and gave the company an “outperform” rating in a research report on Friday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of C$10.06.

The firm has a market capitalization of $1.08 billion and a PE ratio of 34.01.

Knight Therapeutics (TSE:GUD) last posted its quarterly earnings data on Thursday, March 14th. The company reported C$0.04 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of C$0.03 by C$0.01. The firm had revenue of C$3.89 million for the quarter, compared to analysts’ expectations of C$2.55 million. As a group, equities research analysts expect that Knight Therapeutics Inc will post 0.130000001935047 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Knight Therapeutics (GUD) Reaches New 12-Month Low at $7.35” was first posted by Fairfield Current and is owned by of Fairfield Current. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.fairfieldcurrent.com/news/2019/03/15/knight-therapeutics-gud-reaches-new-12-month-low-at-7-35.html.

About Knight Therapeutics (TSE:GUD)

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

Read More: How Do Front-End Loads Impact an Investment?

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply